1. A natural agent, 5-deoxycajanin, mitigates estrogen-deficiency bone loss via modulating osteoclast-osteoblast homeostasis.
- Author
-
Chen Z, Jiang M, Mo L, Zhou C, Huang H, Ma C, Wang Z, Fan Y, Chen Z, Fang B, and Liu Y
- Subjects
- Animals, Mice, Female, Osteogenesis drug effects, Homeostasis drug effects, Mice, Inbred C57BL, Cells, Cultured, Cell Differentiation drug effects, Ovariectomy, Isoflavones pharmacology, Isoflavones therapeutic use, RANK Ligand metabolism, Humans, Molecular Docking Simulation, Mesenchymal Stem Cells drug effects, Mesenchymal Stem Cells metabolism, Osteoclasts drug effects, Osteoblasts drug effects, Osteoblasts metabolism, Estrogens deficiency, Estrogens metabolism, Bone Resorption drug therapy
- Abstract
Hyperactive osteoclasts and hypoactive osteoblasts usually result in osteolytic conditions such as estrogen-deficiency bone loss. Few natural compounds that both attenuating bone resorption and enhancing bone formation could exert effects on this imbalance. 5-Deoxycajanin (5-D), an isoflavonoid extracted from Cajan leaf with estrogen-like properties, were found to have beneficial pharmacological effects on rebalancing the activities of osteoclasts and osteoblasts. This study revealed that 5-D at the same concentration could inhibit osteoclastogenesis of BMMs and promoted osteoblast differentiation of BMSCs. 5-D not only attenuated the fluorescent formation of RANKL-induced F-actin belts and NFATc1, but also activated ALP and RUNX2 expressions. As to downstream factor expressions, 5-D could block osteoclast-specific genes and proteins including NFATc1 and CTSK, while increased osteogenic genes and proteins including OPG and OCN, as confirmed by Real-time PCR and Western Blotting. Additionally, the network pharmacology and molecular docking identified the involvement of 5-D in the MIF and MAPK signaling pathways and the stable binding between 5-D and MAPK2K1. Further Western blot studies showed that 5-D decreased the phosphorylation of p38 and ERK in osteoclasts, but promoted these phosphorylations in osteoblasts. In a female C57BL/6J mouse model of estrogen deficiency-induced bone loss, 5-D demonstrated efficacy in enhancing BMD through attenuating osteoclast activities and promoting osteogenesis. These results underscore the potential application of 5-D on treating osteolysis resulting from hyperactive osteoclasts and hypoactive osteoblasts, shedding light on modulating osteoclast-osteoblast homeostasis., Competing Interests: Declaration of competing interest The authors declare no known competing financial interests or personal relationships that could influence this work., (Copyright © 2024 Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF